The effect of an antibody (Ab) against human IL-6 in the transplant model of psoriasis.
Completed
- Conditions
- psoriasis1000381610014982
- Registration Number
- NL-OMON34138
- Lead Sponsor
- Argen-X
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 11
Inclusion Criteria
Mild to moderate psoriasis vulgaris
Exclusion Criteria
Volunteers can not be taking drugs systemically, including immune-modifiers for other diseases.
Volunteers cannot be be undergoing UV/light therapy
Volunteers should not show Kobner phenomenon at wound sites.
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms link IL-6 inhibition to psoriasis pathogenesis in transplant models?
How does anti-IL-6 antibody efficacy compare to TNF-alpha or IL-17 inhibitors in psoriasis treatment?
Which biomarkers correlate with response to IL-6 blockade in psoriasis transplant studies?
What adverse events are associated with IL-6-targeting therapies in psoriasis and how are they managed?
What combination therapies with IL-6 inhibitors show promise for psoriasis beyond Argen-X's approach?